NPI 1538749114: Open Payments
NPI 1538749114. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$494 in 17 payments from 10 companies in 2025. Trend: 2023 $1,350 · 2024 $1,546 · 2025 $494
Food & beverage: $494
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 2 | $174 |
| ABBVIE INC. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Ardelyx, Inc. | 1 | $25 |
| Organon LLC | 1 | $23 |
| Janssen Biotech, Inc. | 1 | $22 |
| Gilead Sciences, Inc. | 1 | $21 |
| Intercept Pharmaceuticals, Inc. | 1 | $14 |
Products named: REZDIFFRA, RINVOQ, XIFAXAN, ENTYVIO, IQIRVO, IBSRELA, HADLIMA, TREMFYA.
